Source:http://linkedlifedata.com/resource/umls/id/C0074987
PDQ: A saturated derivative of sphingosine. As an inhibitor of protein kinase C (PKC), L-threo-dihydrosphingosine competitively binds to the regulatory phorbol-binding domain of PKC, a kinase involved in tumorigenesis. This agent has been shown to act synergistically with other chemotherapeutic agents and may potentiate chemotherapy drug-induced apoptosis in vitro and in vivo. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41910&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41910&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1568" NCI Thesaurus)